Neurometabolic changes in neonates with congenital heart defects and their relation to neurodevelopmental outcome.


Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
05 2023
Historique:
received: 12 04 2022
accepted: 27 07 2022
revised: 07 07 2022
medline: 12 5 2023
pubmed: 23 8 2022
entrez: 22 8 2022
Statut: ppublish

Résumé

Altered neurometabolite ratios in neonates undergoing cardiac surgery for congenital heart defects (CHD) may serve as a biomarker for altered brain development and neurodevelopment (ND). We analyzed single voxel 3T PRESS H White matter NAA/Cho ratios were lower in CHD neonates compared to healthy controls (group beta estimate: -0.26, std. error 0.07, 95% CI: -0.40 - 0.13, p value <0.001, FDR corrected p value = 0.010). We found no correlation between pre- or postoperative white matter NAA/Cho with ND outcome while controlling for socioeconomic status and CHD diagnosis. Reduced white matter NAA/Cho in CHD neonates undergoing cardiac surgery may reflect a delay in brain maturation. Further long-term MRS studies are needed to improve our understanding of the clinical impact of altered metabolites on brain development and outcome. NAA/Cho was reduced in the white matter, but not the gray matter of CHD neonates compared to healthy controls. No correlation to the 1-year neurodevelopmental outcome (Bayley-III) was found. While the rapid change of NAA/Cho with age might make it a sensitive marker for a delay in brain maturation, the relationship to neurodevelopmental outcome requires further investigation.

Sections du résumé

BACKGROUND
Altered neurometabolite ratios in neonates undergoing cardiac surgery for congenital heart defects (CHD) may serve as a biomarker for altered brain development and neurodevelopment (ND).
METHODS
We analyzed single voxel 3T PRESS H
RESULTS
White matter NAA/Cho ratios were lower in CHD neonates compared to healthy controls (group beta estimate: -0.26, std. error 0.07, 95% CI: -0.40 - 0.13, p value <0.001, FDR corrected p value = 0.010). We found no correlation between pre- or postoperative white matter NAA/Cho with ND outcome while controlling for socioeconomic status and CHD diagnosis.
CONCLUSION
Reduced white matter NAA/Cho in CHD neonates undergoing cardiac surgery may reflect a delay in brain maturation. Further long-term MRS studies are needed to improve our understanding of the clinical impact of altered metabolites on brain development and outcome.
IMPACT
NAA/Cho was reduced in the white matter, but not the gray matter of CHD neonates compared to healthy controls. No correlation to the 1-year neurodevelopmental outcome (Bayley-III) was found. While the rapid change of NAA/Cho with age might make it a sensitive marker for a delay in brain maturation, the relationship to neurodevelopmental outcome requires further investigation.

Identifiants

pubmed: 35995938
doi: 10.1038/s41390-022-02253-y
pii: 10.1038/s41390-022-02253-y
pmc: PMC10172141
doi:

Substances chimiques

Creatine MU72812GK0
Glutamic Acid 3KX376GY7L
Aspartic Acid 30KYC7MIAI
Choline N91BDP6H0X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1642-1650

Informations de copyright

© 2022. The Author(s).

Références

Van Der Linde, D. et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 58, 2241–2247 (2011).
pubmed: 22078432 doi: 10.1016/j.jacc.2011.08.025
Liu, Y. et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int. J. Epidemiol. 48, 455–463 (2019).
pubmed: 30783674 pmcid: 6469300 doi: 10.1093/ije/dyz009
Latal, B. Neurodevelopmental outcomes of the child with congenital heart disease. Clin. Perinatol. 43, 173–185 (2016).
pubmed: 26876129 doi: 10.1016/j.clp.2015.11.012
Khalil, A. et al. Brain abnormalities and neurodevelopmental delay in congenital heart disease: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 43, 14–24 (2014).
pubmed: 23737029 doi: 10.1002/uog.12526
Claessens, N. H. P. et al. Brain injury in infants with critical congenital heart disease: insights from two clinical cohorts with different practice approaches. J. Pediatr. 215, 75–82.e2. https://doi.org/10.1016/j.jpeds.2019.07.017 (2019).
von Rhein, M. et al. Severe congenital heart defects are associated with global reduction of neonatal brain volumes. J. Pediatr. 167, 1259–1263.e1 (2015).
doi: 10.1016/j.jpeds.2015.07.006
Licht, D. J. et al. Brain maturation is delayed in infants with complex congenital heart defects. J. Thorac. Cardiovasc. Surg. 137, 529–537 (2009).
pubmed: 19258059 pmcid: 2701902 doi: 10.1016/j.jtcvs.2008.10.025
Claessens, N. H. P. et al. Delayed cortical gray matter development in neonates with severe congenital heart disease. Pediatr. Res. 80, 668–674 (2016).
pubmed: 27434120 doi: 10.1038/pr.2016.145
Guo, T. et al. White matter injury in term neonates with congenital heart diseases: topology & comparison with preterm newborns. Neuroimage 185, 742–749 (2019).
pubmed: 29890324 doi: 10.1016/j.neuroimage.2018.06.004
Kelly, C. J. et al. Neuroimaging findings in newborns with congenital heart disease prior to surgery: an observational study. Arch. Dis. Child. 104, 1042–1048 (2019).
pubmed: 31243012 doi: 10.1136/archdischild-2018-314822
Claessens, N. H. P. et al. Perioperative neonatal brain injury is associated with worse school-age neurodevelopment in children with critical congenital heart disease. Dev. Med. Child Neurol. 60, 1052–1058 (2018).
pubmed: 29572821 doi: 10.1111/dmcn.13747
Meuwly, E. et al. Postoperative brain volumes are associated with one-year neurodevelopmental outcome in children with severe congenital heart disease. Sci. Rep. 9, 10885 (2019).
Sadhwani, A. et al. Fetal brain volume predicts neurodevelopment in congenital heart disease. Circulation 145, 1108–1119 (2022).
pubmed: 35143287 pmcid: 9007882 doi: 10.1161/CIRCULATIONAHA.121.056305
Rollins, C. K. et al. White matter volume predicts language development in congenital heart disease. J. Pediatr. 181, 42–48.e2 (2017).
pubmed: 27837950 doi: 10.1016/j.jpeds.2016.09.070
Jakab, A. et al. Left temporal plane growth predicts language development in newborns with congenital heart disease. Brain 142, 1270–1281 (2019).
pubmed: 30957841 doi: 10.1093/brain/awz067
Sun, L. et al. Reduced fetal cerebral oxygen consumption is associated with smaller brain size in fetuses with congenital heart disease. Circulation 131, 1313–1323 (2015).
pubmed: 25762062 pmcid: 4398654 doi: 10.1161/CIRCULATIONAHA.114.013051
Rae, C. D. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem. Res. 39, 1–36 (2014).
pubmed: 24258018 doi: 10.1007/s11064-013-1199-5
Blüml, S. et al. Metabolic maturation of the human brain from birth through adolescence: insights from in vivo magnetic resonance spectroscopy. Cereb. Cortex 23, 2944–2955 (2013).
pubmed: 22952278 doi: 10.1093/cercor/bhs283
Pradhan, S. et al. Non-invasive measurement of biochemical profiles in the healthy fetal brain. Neuroimage 219, 117016 (2020).
pubmed: 32526384 doi: 10.1016/j.neuroimage.2020.117016
Kreis, R. et al. Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. Magn. Reson. Med. 48, 949–958 (2002).
pubmed: 12465103 doi: 10.1002/mrm.10304
Kimura, H. et al. Metabolic alterations in the neonate and infant brain during development: evaluation with proton MR spectroscopy. Radiology 194, 483–489 (1995).
pubmed: 7529934 doi: 10.1148/radiology.194.2.7529934
Ross, B. & Bluml, S. Magnetic resonance spectroscopy of the human brain. Anat. Rec. 265, 54–84 (2001).
pubmed: 11323770 doi: 10.1002/ar.1058
Xu, D. & Vigneron, D. Magnetic resonance spectroscopy imaging of the newborn brain—a technical review. Semin. Perinatol. 34, 20–27 (2010).
pubmed: 20109969 pmcid: 2842012 doi: 10.1053/j.semperi.2009.10.003
Abdel Raheem, M. & Mohamed, W. Impact of congenital heart disease on brain development in newborn infants. Ann. Pediatr. Cardiol. 5, 21–26 (2012).
Miller, S. P. et al. Abnormal brain development in newborns with congenital heart disease. N. Engl. J. Med. 357, 1928–1938 (2007).
pubmed: 17989385 doi: 10.1056/NEJMoa067393
Cebeci, B. et al. Brain proton magnetic resonance spectroscopy and neurodevelopment after preterm birth: a systematic review. Pediatr. Res. 91, 1322–1333 https://doi.org/10.1038/s41390-021-01539-x (2022).
Bapat, R., Narayana, P. A., Zhou, Y. & Parikh, N. A. Magnetic resonance spectroscopy at term-equivalent age in extremely preterm infants: association with cognitive and language development. Pediatr. Neurol. 51, 53–59 (2014).
pubmed: 24938140 pmcid: 5942892 doi: 10.1016/j.pediatrneurol.2014.03.011
Feldmann, M. et al. Delayed maturation of the structural brain connectome in neonates with congenital heart disease. Brain Commun. 2, fcaa209 (2020).
Merz, E. C. et al. Neonatal brain metabolite concentrations: associations with age, sex, and developmental outcomes. PLoS One 15, e0243255 (2020).
pubmed: 33332379 pmcid: 7746171 doi: 10.1371/journal.pone.0243255
Cichocka, M., Kozub, J., Karcz, P. & Urbanik, A. Sex differences in brain metabolite concentrations in healthy children – proton magnetic resonance spectroscopy study (1HMRS). Pol. J. Radiol. 83, e24 (2018).
pubmed: 30038675 pmcid: 6047095 doi: 10.5114/pjr.2018.74536
Bucholz, E. M. et al. Socioeconomic status and long-term outcomes in single ventricle heart disease. Pediatrics 146, e20201240 (2020).
Warnes, C. A. et al. Task force 1: the changing profile of congenital heart disease in adult life. J. Am. Coll. Cardiol. 37, 1170–1175 (2001).
pubmed: 11300418 doi: 10.1016/S0735-1097(01)01272-4
R Core Team. R: a language and environment for statistical computing (2020).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289–300 (1995).
Limperopoulos, C. et al. Brain volume and metabolism in fetuses with congenital heart disease: evaluation with quantitative magnetic resonance imaging and spectroscopy. Circulation 121, 26–33 (2010).
pubmed: 20026783 doi: 10.1161/CIRCULATIONAHA.109.865568
Marshall, I., Wardlaw, J., Cannon, J., Slattery, J. & Sellar, R. J. Reproducibility of metabolite peak areas in 1H MRS of brain. Magn. Reson. Imaging 14, 281–292 (1996).
pubmed: 8725194 doi: 10.1016/0730-725X(95)02084-7
Mullins, P. G. et al. Reproducibility of 1H-MRS measurements in schizophrenic patients. Magn. Reson. Med. 50, 704–707 (2003).
pubmed: 14523955 doi: 10.1002/mrm.10598
Tomiyasu, M. et al. Neonatal brain metabolite concentrations: an in vivo magnetic resonance spectroscopy study with a clinical MR system at 3 Tesla. PLoS One 8, 82746 (2013).
doi: 10.1371/journal.pone.0082746
Sabatier, J. et al. Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest. Radiol. 34, 230–235 (1999).
pubmed: 10084669 doi: 10.1097/00004424-199903000-00013
Moffett, J. R., Arun, P., Ariyannur, P. S. & Namboodiri, A. M. N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation. Front. Neuroenergetics 5, 11 (2013).
pubmed: 24421768 pmcid: 3872778 doi: 10.3389/fnene.2013.00011
Volpe, J. J. Overview: normal and abnormal human brain development. Ment. Retardation Developmental Disabilities Res. Rev. 6, 1–5 (2000).
doi: 10.1002/(SICI)1098-2779(2000)6:1<1::AID-MRDD1>3.0.CO;2-J
Volpe, J. J. Encephalopathy of congenital heart disease—destructive and developmental effects intertwined. J. Pediatrics. 164, 962–965 (2014).
doi: 10.1016/j.jpeds.2014.01.002
Dimitropoulos, A. et al. Brain injury and development in newborns with critical congenital heart disease. Neurology 81, 241–248 (2013).
pubmed: 23771484 pmcid: 3770166 doi: 10.1212/WNL.0b013e31829bfdcf
Cheong, J. L. Y. et al. Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and absolute concentrations. AJNR Am. J. Neuroradiol. 27, 1546 (2006).
pubmed: 16908578 pmcid: 7977542
Park, I. S. et al. Metabolic alterations and neurodevelopmental outcome of infants with transposition of the great arteries. Pediatr. Cardiol. 27, 569–576 (2006).
pubmed: 16897317 doi: 10.1007/s00246-004-0730-5
Chau, V. et al. Abnormal brain maturation in preterm neonates associated with adverse developmental outcomes. Neurology 81, 2082–2089 (2013).
pubmed: 24212394 pmcid: 3863348 doi: 10.1212/01.wnl.0000437298.43688.b9
Kendall, G. S. et al. White matter NAA/Cho and Cho/Cr ratios at MR spectroscopy are predictive of motor outcome in preterm infants. Radiology 271, 230–238 (2014).
pubmed: 24475798 doi: 10.1148/radiol.13122679
Augustine, E. M. et al. Can magnetic resonance spectroscopy predict neurodevelopmental outcome in very low birth weight preterm infants? J. Perinatol. 28, 611–618 (2008).
pubmed: 18615089 pmcid: 2844764 doi: 10.1038/jp.2008.66
Schnider, B. et al. Altered brain metabolism contributes to executive function deficits in school-aged children born very preterm. Pediatr. Res. 88, 739–748 (2020).
pubmed: 32590836 pmcid: 7577839 doi: 10.1038/s41390-020-1024-1
Gimenez, M. et al. Proton magnetic resonance spectroscopy reveals medial temporal metabolic abnormalities in adolescents with history of preterm birth. Pediatr. Res. 64, 572–577 (2008).
pubmed: 18596571 doi: 10.1203/PDR.0b013e3181841eab

Auteurs

Céline Steger (C)

Center for MR-Research, University Children's Hospital, Zurich, Switzerland.
Pediatric Cardiology, Pediatric Heart Center, Department of Surgery, University Children's Hospital, Zürich, Switzerland.
Children's Research Center, University Children's Hospital, Zürich, Switzerland.
Neuroscience Center Zürich, University of Zürich, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.

Maria Feldmann (M)

Children's Research Center, University Children's Hospital, Zürich, Switzerland.
Neuroscience Center Zürich, University of Zürich, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.
Child Development Center, University Children's Hospital, Zurich, Switzerland.

Julia Borns (J)

Pediatric Cardiology, Pediatric Heart Center, Department of Surgery, University Children's Hospital, Zürich, Switzerland.
Children's Research Center, University Children's Hospital, Zürich, Switzerland.
Pediatric Cardiology, Inselspital Bern, Bern, Switzerland.

Cornelia Hagmann (C)

Children's Research Center, University Children's Hospital, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.
Department of Neonatology and Pediatric Intensive Care, University Children's Hospital, Zurich, Switzerland.

Beatrice Latal (B)

Children's Research Center, University Children's Hospital, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.
Child Development Center, University Children's Hospital, Zurich, Switzerland.

Ulrike Held (U)

University of Zurich, Zurich, Switzerland.
Department of Epidemiology, Biostatistics and Prevention Institute UZH, Zürich, Switzerland.

András Jakab (A)

Center for MR-Research, University Children's Hospital, Zurich, Switzerland.
Children's Research Center, University Children's Hospital, Zürich, Switzerland.
Neuroscience Center Zürich, University of Zürich, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.

Ruth O'Gorman Tuura (R)

Center for MR-Research, University Children's Hospital, Zurich, Switzerland.
Children's Research Center, University Children's Hospital, Zürich, Switzerland.
Neuroscience Center Zürich, University of Zürich, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.

Walter Knirsch (W)

Pediatric Cardiology, Pediatric Heart Center, Department of Surgery, University Children's Hospital, Zürich, Switzerland. walter.knirsch@kispi.uzh.ch.
Children's Research Center, University Children's Hospital, Zürich, Switzerland. walter.knirsch@kispi.uzh.ch.
University of Zurich, Zurich, Switzerland. walter.knirsch@kispi.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH